Skip to main content

Advances in Small Trials dEsign for Regulatory Innovation and eXcellence

Ziel

"ASTERIX will contribute towards the expected impact listed in the work program by delivering validated innovative statistical design methodologies for cost efficient clinical trials deriving reliable results from trials in small population groups, especially focusing on rare diseases. It directly addresses the rights of the estimated 30 million European patients suffering from rare diseases to the same quality or treatment as other patients. By choosing an integrated approach leveraging statistical methods, smartly combining observational and clinical data as well as improved sequential and adaptive approaches ASTERIX will improve statistical power of clinical trial design in small populations. ASTERIX will systematically include patients and the patient perspective into its research, but moreover develop the approach to involve patients in clinical trial design in a methodological sound manner. Pre-clinical data, historical data on disease characteristics, and benefit and risk as perceived by patients will systematically inform and weigh relevant endpoint measures. Thus the clinical value of trial results will be enhanced considerably. Key methodological innovations include: new standards of evidence that take into account the rare prevalence of disease, leveraging prior information and the availability of multiple endpoints, enabling adaptive designs and sequential meta-analysis using multiple endpoints and providing a blue print to pro-actively share information on trials in the planning stage. The latter will ensure that each new trial in an orphan disease provides the optimum additional knowledge for patient treatment. Relevance and clinical value of the newly designed methodological approaches are validated twofold. Firstly, by cross testing with available clinical trial data of a broad range of highly relevant rare diseases and secondly, by assessing the methods against current and improved regulatory approval strategies."

Aufforderung zur Vorschlagseinreichung

FP7-HEALTH-2013-INNOVATION-1
Andere Projekte für diesen Aufruf anzeigen

Koordinator

UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Adresse
Heidelberglaan 100
3584 CX Utrecht
Niederlande

Auf der Karte ansehen

Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Caroline Van Baal (Dr.)
EU-Beitrag
€ 750 058

Beteiligte (6)

MEDIZINISCHE HOCHSCHULE HANNOVER
Deutschland
EU-Beitrag
€ 525 200
Adresse
Carl-neuberg-strasse 1
30625 Hannover

Auf der Karte ansehen

Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Frank Dittrich (Mr.)
MEDIZINISCHE UNIVERSITAET WIEN
Österreich
EU-Beitrag
€ 515 401
Adresse
Spitalgasse 23
1090 Wien

Auf der Karte ansehen

Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Wolfgang Dorda (Prof.)
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Niederlande
EU-Beitrag
€ 466 640
Adresse
Meibergdreef 15
1105AZ Amsterdam

Auf der Karte ansehen

Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Sylvia Georgiev (Ms.)
UNIVERSITAT AUTONOMA DE BARCELONA
Spanien
EU-Beitrag
€ 512 442
Adresse
Edif A Campus De La Uab Bellaterra Cerdanyola V
08193 Cerdanyola Del Valles

Auf der Karte ansehen

Aktivitätstyp
Higher or Secondary Education Establishments
Kontakt Verwaltung
Francisca Rabadán Sotos (Ms.)
STATISTICIANS IN THE PHARMACEUTICALINDUSTRY LIMITED LBG
United Kingdom
EU-Beitrag
€ 68 150
Adresse
Durford Mill
GU31 5AZ Petersfield

Auf der Karte ansehen

Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Alun Bedding (Mr.)
VERENIGING SAMENWERKENDE OUDER- EN PATIENTENORGANISATIES
Niederlande
EU-Beitrag
€ 161 990
Adresse
Vredehofstraat 31
3761HA Soest

Auf der Karte ansehen

Aktivitätstyp
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
Kontakt Verwaltung
Cor Oosterwijk (Mr.)